The preferred choice for chemotherapy-induced nausea and vomiting (CINV) management. Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared adverse reactions among patients undergoing cancer treatment, severely affecting treatment compliance and quality of life. As a new generation of NK1 receptor antagonists, Fosaprepitant Dimeglumine, with its pharmacological properties of high selectivity and high affinity, can strongly block the vomiting signaling pathway mediated by substance P.
Clinical data confirm that this product exhibits excellent control effects on acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). A single dose administration can achieve long-acting antiemesis with good tolerance. When combined with 5-HT3 receptor antagonists and dexamethasone, it constructs a comprehensive and full-cycle CINV protection system.
From the convenience of administration to the stability of efficacy, Fosaprepitant Dimeglumine provides a better choice for clinical practice, helping patients get through the chemotherapy cycle smoothly and making cancer treatment more compassionate.
Post time: Dec-09-2025
